Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Experience with insurance coverage issues and obtaining access to systemic bevacizumab for HOCF among HHT centers

From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

StatementPercent of Centers
Able to obtain insurance coverage for most or all patients70%
Obtaining insurance coverage is a cumbersome process for most patients50%
Have obtained bevacizumab using “Genentech Access to Care Foundation” compassionate use program20%
Have had little or no trouble with Medicare approval of bevacizumab35%
Able to obtain insurance coverage for oral anti-angiogenic therapies in cases of systemic bevacizumab insurance denial5%
Frequently forced to search for alternative treatments because of insurance denial0%